Paclitaxel

Generic Name
Paclitaxel
Brand Names
Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
Drug Type
Small Molecule
Chemical Formula
C47H51NO14
CAS Number
33069-62-4
Unique Ingredient Identifier
P88XT4IS4D
Background

Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication

Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxaneยฎ is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions
Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
Associated Therapies
-
Clinical Trials
Related News

Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma

First Posted Date
2003-07-11
Last Posted Date
2013-01-10
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
240
Registration Number
NCT00003350
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Eastern Cooperative Oncology Group, Boston, Massachusetts, United States

Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma

Phase 2
Completed
Conditions
Sarcoma
First Posted Date
2003-07-11
Last Posted Date
2023-06-15
Lead Sponsor
Eastern Cooperative Oncology Group
Target Recruit Count
33
Registration Number
NCT00003008
Locations
๐Ÿ‡บ๐Ÿ‡ธ

University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States

Paclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer

First Posted Date
2003-07-09
Last Posted Date
2013-04-11
Lead Sponsor
Gynecologic Oncology Group
Registration Number
NCT00023907
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States

๐Ÿ‡บ๐Ÿ‡ธ

MBCCOP - University of Illinois at Chicago, Chicago, Illinois, United States

๐Ÿ‡บ๐Ÿ‡ธ

Ireland Cancer Center, Cleveland, Ohio, United States

and more 41 locations

Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix

First Posted Date
2003-07-09
Last Posted Date
2018-10-17
Lead Sponsor
Gynecologic Oncology Group
Target Recruit Count
513
Registration Number
NCT00064077
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States

Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

First Posted Date
2003-07-09
Last Posted Date
2021-10-19
Lead Sponsor
GOG Foundation
Target Recruit Count
1381
Registration Number
NCT00063999
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Emory Saint Joseph's Hospital, Atlanta, Georgia, United States

๐Ÿ‡บ๐Ÿ‡ธ

Mason District Hospital, Havana, Illinois, United States

๐Ÿ‡บ๐Ÿ‡ธ

Greater Baltimore Medical Center, Baltimore, Maryland, United States

and more 640 locations

Combination Chemotherapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer

First Posted Date
2003-07-01
Last Posted Date
2015-12-23
Lead Sponsor
AGO Study Group
Target Recruit Count
105
Registration Number
NCT00031954
Locations
๐Ÿ‡ฉ๐Ÿ‡ช

Zentralkrankenhaus, Bremen, Germany

๐Ÿ‡ฉ๐Ÿ‡ช

Medizinische Klinik I, Dresden, Germany

๐Ÿ‡ฉ๐Ÿ‡ช

Evangelisches Krankenhaus, Dusseldorf, Germany

and more 15 locations

Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer

Phase 3
Completed
Conditions
Lung Cancer
First Posted Date
2003-07-01
Last Posted Date
2021-09-09
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
1
Registration Number
NCT00028938
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States

Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer

First Posted Date
2003-06-27
Last Posted Date
2010-04-08
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
39
Registration Number
NCT00063401
Locations
๐Ÿ‡บ๐Ÿ‡ธ

ImClone Investigational Site, Philadelphia, Pennsylvania, United States

Tarceva Surgery for Resectable Stage IIIA(N2) and IIIB (T4 N2) Non-Small-Cell Lung Cancer

First Posted Date
2003-06-25
Last Posted Date
2016-05-09
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
5
Registration Number
NCT00063258
Locations
๐Ÿ‡บ๐Ÿ‡ธ

MD Anderson Cancer Center, Houston, Texas, United States

Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus

Phase 2
Terminated
Conditions
Sarcoma
First Posted Date
2003-06-25
Last Posted Date
2018-04-12
Lead Sponsor
Gynecologic Oncology Group
Registration Number
NCT00003054
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Pennsylvania Hospital, Philadelphia, Pennsylvania, United States

๐Ÿ‡บ๐Ÿ‡ธ

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

๐Ÿ‡บ๐Ÿ‡ธ

Indiana University Cancer Center, Indianapolis, Indiana, United States

and more 62 locations
ยฉ Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy